MUSE Stem Cells:
The Complete Guide
MUSE stem cells — Multilineage-differentiating Stress-Enduring cells — are a rare, naturally pluripotent subpopulation of mesenchymal stem cells that home to damaged tissue, replace dying cells, and regenerate function. No genetic reprogramming. No tumor risk. Backed by 85+ peer-reviewed studies and multiple completed Phase II clinical trials.
In This Complete Guide
- What Are MUSE Stem Cells?
- The Discovery (2010)
- Why "Stress-Enduring" Matters
- How MUSE Cells Work
- MSC vs MUSE: Detailed Breakdown
- MUSE vs MSCs vs ESCs vs iPSCs
- Which Cells for Which Condition?
- Why MUSE Cells Don't Form Tumors
- Clinical Evidence
- Routes of Administration
- MUSE Cells + Exosomes
- Conditions Under Investigation
- MUSE at The Stem Cell Club
- Locations & Availability
- Medical Director
- FAQ
- Research Citations
- Book a Consultation
What are MUSE stem cells?
MUSE stem cells (Multilineage-differentiating Stress-Enduring cells) are a rare, naturally occurring subpopulation of adult mesenchymal stem cells discovered in 2010 by Professor Mari Dezawa at Tohoku University, Japan. They make up roughly 1–3% of standard MSC cultures and are uniquely able to differentiate into cells from all three embryonic germ layers — without genetic reprogramming and without forming tumors. MUSE cells home directly to damaged tissue via the S1P–S1PR2 signaling axis, where they replace dying cells with healthy ones, making them a tissue-replacement therapy rather than a signaling therapy.
Regular MSCs vs. MUSE MSCs
Modulate your immune system, polarize macrophages, and induce regeneration mostly by using your own body's potential. They signal — your body does the work.
Replace injured cells directly. They differentiate into the damaged cell type and take over its function — physically rebuilding tissue rather than just signaling for repair.
What Are MUSE Stem Cells?
A 60-second primer on the most advanced naturally-occurring stem cell in the human body.
When most people hear "stem cells," they're picturing a single thing: the body's repair kit. But not all stem cells do the same job — and not all stem cells carry the same risks.
MUSE cells are different from anything else in regenerative medicine. Standard mesenchymal stem cells (MSCs) help your body heal by signaling — they release helpful molecules that calm inflammation and tell nearby cells to repair themselves. They're like a coach on the sidelines.
MUSE cells go further. They are naturally pluripotent, meaning they can become almost any cell type in the body — heart muscle, neurons, liver cells, kidney cells, skin cells. After being infused, MUSE cells actively migrate through the bloodstream to areas of tissue damage, engulf the dying cells, and physically replace them with healthy, functional new cells.
They're not the coach. They're the player.
The simple framework
- Standard stem cells (MSCs) = help your body repair itself
- MUSE stem cells = may help your body actually rebuild damaged tissue
Both have a place in regenerative medicine. The right one depends on what's happening inside your body.
Important: MUSE cells are an endogenous cell type — they exist naturally in your body right now, in your bone marrow, fat, dermis, and connective tissues. They make up only about 1–3% of your total mesenchymal stem cell population, which is why isolating and concentrating them for therapy is such a scientific breakthrough.
The Discovery
How a Tohoku University research team identified the cell that solved a 30-year problem in regenerative medicine.
For three decades, regenerative medicine had a fundamental problem: every pluripotent stem cell that could rebuild damaged tissue also carried significant risks.
- Embryonic stem cells (ESCs) are pluripotent but raise ethical concerns and form teratomas (tumors).
- Induced pluripotent stem cells (iPSCs) require genetic reprogramming with viral vectors and also carry tumor risk.
- Standard MSCs are safe and ethical — but only multipotent, limited mostly to bone, cartilage, fat, and muscle lineages.
Researchers needed a stem cell that combined the regenerative power of pluripotency with the safety of an adult-derived MSC. For thirty years, that cell wasn't believed to exist.
In 2010, Professor Mari Dezawa and her team at Tohoku University Graduate School of Medicine in Sendai, Japan published a paper in the Proceedings of the National Academy of Sciences describing a unique multipotent population they had isolated from adult human mesenchymal cell cultures. They named them MUSE cells — for their two defining traits: multilineage differentiation and stress endurance.
Why this matters: MUSE cells were the first stem cell ever identified that combined three previously incompatible properties — naturally pluripotent (can become any cell type), adult-sourced (no ethical concerns, no genetic reprogramming), and non-tumorigenic (no teratoma formation in any study to date).
In the 15 years since, more than 120 peer-reviewed papers have been published on MUSE cell biology, and multiple Phase II human clinical trials have been completed in Japan for heart attack, stroke, ALS, spinal cord injury, and skin disease — all without serious adverse events.
Why "Stress-Enduring" Matters
The single biological property that explains why MUSE cells survive — and why standard stem cells often don't.
The "SE" in MUSE — Stress-Enduring — isn't marketing language. It describes a measurable biological property that's central to how MUSE cells work and why they're unusually safe.
Most cells, including most stem cells, die when exposed to harsh conditions: low oxygen, low nutrients, enzymatic digestion, repeated freezing and thawing. MUSE cells survive these conditions. In fact, the original isolation method described by Dezawa's lab uses long-duration enzymatic stress as the selection mechanism — only MUSE cells live through it.
This matters for three reasons:
1. They survive the journey to damaged tissue
When tissue is damaged — whether from a heart attack, a stroke, a degenerative disease, or chronic inflammation — the local environment becomes hostile. Standard stem cells injected into this environment often die before they can do their job. MUSE cells survive long enough to engraft.
2. They survive cryopreservation and clinical-grade banking
For a stem cell therapy to be practical at scale, the cells need to survive freezing, storage, shipping, and thawing without losing function. MUSE cells maintain chromosomal stability and viability through long-term culture and cryopreservation — critical for any reliable allogeneic (donor-derived) cell product.
3. Stress is what activates them
Interestingly, MUSE cells produced from regular MSCs through controlled stress exposure can revert back to standard MSCs if the stress is removed. They're the same underlying cell — just in a different "mode." Stress endurance is what unlocks their pluripotent regenerative capacity.
Clinical translation: Stress endurance is why MUSE cells can be banked, shipped frozen, thawed at the bedside, and infused into a patient with high viability — a logistical reality that's much harder to achieve with most other stem cell types.
How MUSE Cells Work
The four-step biological mechanism that distinguishes MUSE cells from every other stem cell therapy.
Damage Detection
When tissue is injured, dying cells release sphingosine-1-phosphate (S1P) as a distress signal. MUSE cells uniquely express the S1PR2 receptor — letting them detect this signal anywhere in the body.
Active Homing
Following the S1P gradient, MUSE cells migrate through the bloodstream and exit blood vessels at the site of damage. Standard MSCs lack this targeting capability and tend to get trapped in the lungs after IV infusion.
Phagocytosis & Differentiation
MUSE cells engulf the dying cells (phagocytosis), then spontaneously differentiate into the same cell type they consumed. In a damaged heart, they become cardiac muscle cells. In a brain infarct, they become neurons.
Tissue Integration
The newly differentiated cells integrate into existing tissue, replacing damaged cells with healthy, functional ones. This is structural regeneration — the actual rebuilding of tissue at the cellular level, not a temporary signaling effect.
Why this is different from MSC therapy: Standard MSCs primarily work through paracrine signaling — secreting helpful molecules nearby. They don't usually become the new tissue. MUSE cells go further: they actively home to damage, consume dying cells, and physically replace them. Research has confirmed this mechanism across heart, brain, liver, kidney, skin, and spinal cord tissue.
MUSE MSC vs. Regular MSC: The Detailed Breakdown
Eleven critical differences between standard mesenchymal stem cells and the MUSE subpopulation that came from them.
| Feature | Regular Stem Cells (MSC) | MUSE Cells |
|---|---|---|
| Definition | Stem cells such as mesenchymal or embryonic stem cells. | Multilineage-differentiating Stress-Enduring (MUSE) cells. |
| Discovery | Known since the early 20th century. | Discovered in 2010 by Dr. Mari Dezawa (Tohoku University, Japan). |
| Source | Bone marrow, adipose tissue, umbilical cord, etc. | Rare subpopulation within mesenchymal stem cells (bone marrow, fat, fibroblasts, Wharton's jelly). |
| Stress Resistance | Sensitive to environmental stress. | Highly stress-tolerant; survive harsh conditions that kill other stem cells. |
| Differentiation | Lineage-restricted depending on type — typically mesoderm only (bone, cartilage, fat, muscle). | Naturally pluripotent; can differentiate into cells from all three germ layers (ectoderm, mesoderm, endoderm). |
| Tumor Risk | Some types (e.g., embryonic) may form teratomas. | Non-tumorigenic — no tumor formation observed in any clinical study. |
| Ethics | Ethical concerns for embryonic stem cells. | No ethical concerns — derived from adult tissues (umbilical cord, bone marrow, fat). |
| Immunogenicity | Possible immune rejection; HLA matching may be required. | Immunologically privileged (~90% HLA-G expression); low rejection risk; no HLA matching needed. |
| Regenerative Mechanism | Paracrine effects and signaling — stimulate your body to repair itself. | Direct tissue integration and regeneration — physically replace damaged cells. |
| Clinical Use | Regenerative medicine, orthopedics, joints, autoimmune support. | Regenerative therapy, neurology, autoimmune disease, organ regeneration, anti-aging. |
| Clinical Safety | Depends on source and purity. | Demonstrated high safety in human clinical trials across 7+ conditions. |
Key insight: MUSE cells and standard MSCs are not separate cells — MUSE cells are a rare subpopulation within the MSC pool. The same biological cell can exist in either state: when exposed to controlled stress, MSCs that are MUSE-capable enter their pluripotent "MUSE mode." Remove the stress, and they revert to standard MSC behavior. Stress endurance is the activation switch.
MUSE Cells vs. Other Stem Cells
How MUSE cells compare to embryonic, induced pluripotent, and standard mesenchymal stem cells.
| Property | Embryonic (ESC) | iPSC | Standard MSC | MUSE Cell |
|---|---|---|---|---|
| Pluripotent | ✓ Yes | ✓ Yes | ✗ Multipotent only | ✓ Yes — naturally |
| Tumor / teratoma risk | High | High | Low | None reported |
| Genetic reprogramming required | No | Yes (viral vectors) | No | No |
| Ethical concerns | Yes | No | No | No |
| Active tissue homing | No | No | Limited | Yes — S1P axis |
| HLA-G expression (immune tolerance) | Low | Low | ~20% | ~90% |
| HLA matching required | Yes | Yes | Sometimes | No |
| Immunosuppressive drugs needed | Yes | Yes | Sometimes | No |
| Mechanism of repair | Differentiation | Differentiation | Paracrine signaling | Direct tissue replacement |
| Years in human clinical trials | 20+ | 10+ | 25+ | 10+ |
MUSE cells are currently the only known cell type to combine natural pluripotency with non-tumorigenic safety in adult human tissue.
MSC vs. MUSE: Clinical Use Overview
Standard MSCs and MUSE cells are not interchangeable. Each has a clear strength depending on the underlying problem.
| Clinical Situation | MSCs (Standard) | MUSE Cells |
|---|---|---|
| Inflammatory & Autoimmune Diseases | Strong immunomodulation — autoimmune disease, cytokine storm, graft-versus-host disease. | Moderate immunomodulation, supportive role. |
| Orthopedics & Joints | Cartilage repair, osteoarthritis, tendon and ligament injuries — primary tool. | Support regeneration, but usually a secondary role. |
| Acute Injury (Trauma, Burns) | Reduce inflammation, accelerate healing via paracrine signaling. | Direct tissue integration and structural repair. |
| Neurological Diseases | Neuroprotection and anti-inflammatory effects. | Differentiation into neural cells and integration into damaged brain or spinal cord tissue. |
| Organ Regeneration (Heart, Liver, Kidney) | Mainly paracrine support and anti-inflammatory effects. | Direct differentiation into organ cells and structural repair. |
| Chronic Degenerative Diseases | Slows degeneration through trophic support. | Potential structural regeneration of damaged tissue. |
| Systemic Regenerative Therapy / Anti-Aging | Support immune balance and tissue environment. | Replace damaged cells and promote tissue renewal. |
MSCs are best for
Immune modulation and inflammation control. Autoimmune disease, joint disease, post-injury recovery, systemic anti-inflammatory support.
MUSE cells are best for
Tissue replacement and structural regeneration. Neurological injury, organ damage, chronic degenerative disease, conditions where signaling alone isn't enough.
The simple rule
Need to control inflammation? → MSCs.
Need to rebuild tissue? → MUSE cells.
Need both? → Combination protocol.
How we use this clinically: The strongest results in regenerative medicine usually come from combination protocols — using standard MSCs to calm inflammation and prepare the tissue environment, then using MUSE cells to physically replace what's been damaged. During your free consultation, we'll match the protocol to your specific condition rather than defaulting to a one-size-fits-all approach.
Why MUSE Cells Don't Form Tumors
Three biological mechanisms that distinguish MUSE cells from every other pluripotent stem cell ever studied.
The biggest limitation of pluripotent stem cells has always been tumor formation. Embryonic and induced pluripotent stem cells routinely form teratomas — tumors composed of multiple tissue types — when transplanted into living animals. This is why those cell types have struggled to move from laboratory science to bedside therapy.
MUSE cells solve this problem through three biological features that suppress the molecular pathways responsible for uncontrolled growth:
Telomerase is the enzyme that allows cells to divide indefinitely — it's overexpressed in nearly every cancer cell. MUSE cells express telomerase at very low levels, similar to normal somatic cells, which limits their replicative capacity to what's needed for tissue repair.
Let-7 is a tumor-suppressor microRNA that is downregulated in most human cancers. MUSE cells express Let-7 at high levels, which silences the oncogenic pathways (RAS, MYC, HMGA2) that would otherwise drive uncontrolled growth.
HLA-G is a non-classical major histocompatibility molecule that inhibits NK cells and cytotoxic T-cell activation. MUSE cells express HLA-G at approximately 90% — compared to less than 20% in standard MSCs — which makes them tolerated by the recipient's immune system without HLA matching and without immunosuppressive drugs.
The clinical track record: Across all completed and ongoing human clinical trials of MUSE cell therapy — including trials in heart attack, stroke, ALS, epidermolysis bullosa, cervical spinal cord injury, and neonatal brain injury — no teratoma formation and no serious adverse events related to MUSE cell treatment have been reported.
What the Research Shows
Completed and ongoing human clinical trials of MUSE cell therapy across seven indications.
Acute Myocardial Infarction
Heart attack patients received a single IV dose of donor MUSE cells. Ejection fraction improved from approximately 41% to 52% — a double-digit gain. In cardiology, even a 5% improvement is clinically meaningful.
Phase II Complete — First-in-HumanIschemic Stroke
Randomized, double-blind, placebo-controlled trial. IV-administered MUSE cells without HLA matching. Functional recovery was statistically significant and sustained through 52 weeks of follow-up.
Phase II Randomized Controlled TrialCervical Spinal Cord Injury
10 patients with recent cervical spinal cord injuries received donor MUSE cells. Safety confirmed, with meaningful improvements in motor function, daily activities, and quality of life.
2024 Multicenter Trial — JapanALS (Lou Gehrig's Disease)
First MUSE cell trial to test multiple doses (6 IV injections). Confirmed safety of repeated administration with potential therapeutic effects in this devastating neurodegenerative condition.
Phase II — Repeated DosingEpidermolysis Bullosa
Five patients with chronic, painful skin ulcers unresponsive to other treatments received a single IV dose. Treatment improved erosion area and reduced ulcer size.
Phase I/II — Open LabelNeonatal Brain Injury
MUSE cells evaluated for neonatal hypoxic-ischemic encephalopathy — brain injury from oxygen deprivation at birth. Safety and therapeutic effects were reported.
Investigator-Initiated TrialConditions in Active Preclinical & Early Investigation
Beyond the seven indications already in clinical trials, MUSE cell efficacy has been demonstrated in preclinical models of liver cirrhosis, chronic kidney disease, diabetic skin ulcers, pulmonary fibrosis, intracerebral hemorrhage, retinal degeneration, and inflammatory bowel disease. Many of these are expected to enter human trials in the next 2–5 years.
Clinical context: MUSE cell therapy is most extensively studied and clinically advanced in Japan, which has the world's most progressive regulatory framework for regenerative medicine. In the United States, MUSE cell therapy remains investigational and is offered through licensed clinics under physician supervision. Outcomes vary by individual and condition.
Considering MUSE Cell Therapy?
Speak with a licensed nurse practitioner about whether MUSE cells, premium MSC therapy, or a combination protocol is right for your specific condition. Free, no-pressure consultation.
Schedule Free ConsultationRoutes of Administration
How MUSE cells are delivered depends on the condition being treated.
One of the practical advantages of MUSE cell therapy is delivery flexibility. The same cell product can be administered through multiple routes depending on whether the goal is systemic effect, targeted joint repair, or direct delivery to the central nervous system.
IV Infusion
The most common route. Cells circulate systemically and home to damaged tissue via the S1P axis. Standard infusion is 10–15 minutes.
Intra-Articular (Joint)
Direct injection into joints (knee, shoulder, hip, spine) for targeted regeneration in degenerative joint disease.
Intranasal
Nasal drops or nebulization can deliver cells and exosomes directly to the central nervous system for neuroinflammation and cognitive support.
Intramuscular
Used when a more pronounced and prolonged release is desired, particularly for autoimmune conditions.
Intradermal
Mesodermal injections for skin rejuvenation and dermatologic indications, including pilot studies in rosacea and melasma.
Topical
Topical applications, including formulations for the eyes, are an active area of research and have shown encouraging results in early veterinary and clinical observations.
Clinical protocol: Published Phase II trials administered approximately 1.5 × 10⁷ MUSE cells in 15 mL, thawed and diluted in Ringer's solution, delivered IV over 10–15 minutes. Higher doses are used in some clinical settings; in our clinical experience, dose response matters and protocols should be matched to the individual case.
MUSE Cells + Exosomes
Why the most advanced regenerative protocols rarely use a single agent.
In regenerative medicine, combination protocols consistently outperform single-agent therapy. The reason is that different biological tools do different jobs — and healing is rarely a one-step process.
The clearest example is the relationship between MUSE cells and exosomes (small extracellular vesicles released by cells, packed with proteins, lipids, and microRNAs that drive intercellular communication).
Here's the simplest way to think about it:
- Exosomes = send the message — they trigger gene expression and prepare tissue for repair. Effects can persist up to 21 days after a single dose by modulating gene expression long after the particles themselves have been cleared.
- Standard MSCs = support the repair — they reduce inflammation and modulate the immune system through paracrine signaling.
- MUSE cells = rebuild the structure — they engraft into damaged tissue and physically replace dying cells.
Exosomes have been shown to penetrate the blood-brain barrier when delivered intranasally — a property that's particularly relevant for neuroinflammation, cognitive decline, and pediatric neurodevelopmental conditions, all of which appear to involve underlying inflammatory mechanisms.
Why combination protocols work better
A typical advanced regenerative protocol might combine a high-dose IV MUSE infusion (for systemic tissue repair) with exosomes (for gene-expression priming and inflammation control), targeted joint injections (for localized degenerative disease), and supportive IV nutrition. Each layer addresses a different aspect of the underlying problem.
Important caveat: The biggest current limitation in exosome therapy is the lack of a universal standardization system. Different labs measure exosomes differently — and the numbers don't always compare. Quality, sourcing, and protocol matter enormously. Where you go and what you receive isn't a small consideration.
Conditions Under Active Investigation
The full landscape of indications where MUSE cell therapy has shown clinical or preclinical promise.
Cardiovascular
Neurological
Orthopedic & Musculoskeletal
Autoimmune & Inflammatory
Organ & Tissue Disease
FTC compliance note: MUSE cell therapy is investigational. Inclusion of a condition above means published research has shown clinical or preclinical signal — not that MUSE cells are an approved treatment for that condition. Most patients report meaningful improvement from regenerative protocols, but outcomes vary by individual. We do not promise cures.
MUSE Cells at The Stem Cell Club
Premium regenerative therapy at honest, transparent pricing — without the offshore travel or the $25,000+ price tag.
For most of the last decade, U.S. patients interested in MUSE cell therapy had two options: travel to Japan, Mexico, or the Caribbean for treatment costing $25,000–$50,000, or wait for FDA-approved trials with very narrow eligibility windows.
The Stem Cell Club was built to change that. We bring premium, U.S.-administered regenerative protocols — including APEX™ MUSE Cells — to patients in St. George, Utah and Las Vegas, Nevada at transparent, accessible pricing. No sales commissions. No broker markups. No pressure.
Our APEX™ MUSE Cell protocol
APEX™ MUSE Cells are sourced from rigorously screened umbilical cord tissue, isolated and expanded under cleanroom conditions, and shipped frozen for bedside thaw and infusion. Every dose is administered under the medical direction of a licensed nurse practitioner.
Why patients choose us
MUSE cell therapy is more advanced and more expensive to produce than standard MSC therapy — so we provide pricing during your free consultation, where we can match the protocol to your specific condition. Most patients find our MUSE pricing significantly below offshore alternatives.
No medical tourism. Treatments performed under the direction of Savinder Virk, APRN, FNP at our Utah and Nevada clinics.
We don't promise cures. We tell you what published research shows, what outcomes are realistic for your condition, and when MUSE cells are not the right protocol.
For many conditions, the strongest protocols combine MUSE cells with our standard APEX™ Wharton's jelly MSC product, exosomes, IV nutrition, and targeted joint injections. We build the protocol around the patient — not the product.
Where to Get MUSE Stem Cell Therapy
MUSE cell therapy is available at our flagship clinics in Utah and Nevada, plus a growing network of co-branded partner clinics across the United States.
Flagship Clinics
St. George, Utah
640 E. 700 S. Ste 304
St. George, UT 84790
Serving Southern Utah, Mesquite, Cedar City, and the Las Vegas / Phoenix corridor.
(435) 281-2999Las Vegas, Nevada
9830 W. Tropicana Ave Ste 165
Las Vegas, NV 89147
Serving Las Vegas, Henderson, Summerlin, and the broader Southern Nevada region.
(435) 281-2999Partner Clinic Network
Co-Branded Partner Clinics Across the United States
The Stem Cell Club partners with select regenerative medicine clinics across the country, giving patients access to the same APEX™ MUSE Cell product, the same clinical protocols, and the same transparent pricing — closer to home.
Currently active partners include: LC Prime Regenerative (National City, CA), with additional partner clinics being added across multiple states.
Or schedule a free consultation online and we'll match you with the closest network location.
Physician-Administered Care
Every MUSE cell protocol at The Stem Cell Club is administered under licensed medical supervision.
Savinder Virk, APRN, FNP
Savinder Virk serves as the Medical Director for The Stem Cell Club, overseeing all clinical protocols across our St. George, Utah and Las Vegas, Nevada locations. She is injection-certified and holds active licensure in Nevada (#821860) and Texas (#1069876). NPI: 1033735014. She earned her Master's degree from United States University and brings extensive clinical experience in regenerative and integrative medicine.
Frequently Asked Questions About MUSE Stem Cells
Everything patients ask before scheduling a consultation.
MUSE is an acronym for Multilineage-differentiating Stress-Enduring cells. The name reflects two defining traits: the ability to differentiate into many cell types (all three embryonic germ layers), and an exceptional ability to survive harsh conditions — low oxygen, nutrient deprivation, enzymatic stress — that kill other stem cells.
MUSE cells are a rare subpopulation found within MSC cultures (about 1–3%). Standard MSCs are multipotent (limited to bone, cartilage, fat, muscle) and work mainly through paracrine signaling. MUSE cells are naturally pluripotent (can become almost any cell type), actively home to damaged tissue via the S1P–S1PR2 signaling axis, and physically replace damaged cells through direct differentiation. They also express HLA-G at much higher levels (~90% vs <20% in MSCs), giving them stronger immune tolerance.
MUSE cells have demonstrated an exceptional safety profile across all preclinical and clinical studies to date. No teratoma formation has been observed in any study. This is attributed to low telomerase activity and Let-7 microRNA expression, which suppress the molecular pathways responsible for uncontrolled growth. Across human clinical trials in heart attack, stroke, ALS, skin disease, spinal cord injury, and neonatal brain injury, no serious adverse events related to MUSE cell treatment have been reported.
MUSE cells are most commonly administered via IV infusion, similar to any standard IV therapy. The infusion typically takes 10–15 minutes. No surgery is required. After infusion, the cells actively home to sites of tissue damage. Targeted protocols (intra-articular joint injection, intranasal delivery for neurological indications, intramuscular injection for autoimmune conditions) may also be used depending on the condition.
MUSE cell therapy is priced separately from our standard $1,999 umbilical cord MSC therapy because production is significantly more complex and the cell type is more advanced. We provide MUSE pricing during your free consultation so we can match the protocol to your specific condition and goals. Most patients find our MUSE pricing far below the $25,000–$50,000 commonly quoted at offshore clinics.
Completed Phase II clinical trials cover acute myocardial infarction (heart attack), ischemic stroke, ALS, epidermolysis bullosa, cervical spinal cord injury, and neonatal brain injury. Preclinical research also shows efficacy in liver cirrhosis, chronic kidney disease, diabetic skin ulcers, pulmonary fibrosis, and intracerebral hemorrhage. MUSE cell therapy remains investigational, and outcomes vary by individual.
When tissue is damaged, dying cells release sphingosine-1-phosphate (S1P) as a distress signal. MUSE cells uniquely express the S1PR2 receptor, allowing them to detect this signal and migrate directly to the damaged area through the bloodstream — a property standard MSCs lack. This is also why standard MSCs tend to get trapped in the lungs after IV infusion while MUSE cells reach the actual site of injury.
No. MUSE cells express HLA-G at approximately 90%, which inhibits NK cells and cytotoxic T-cell activation. This allows allogeneic (donor-derived) MUSE cells to be used without immunosuppressive drugs and without HLA matching between donor and recipient. Donor MUSE cells have been shown to survive in recipient tissue for up to six months without rejection.
Unlike standard MSCs (which are typically cleared within ~6 months), MUSE cells that successfully integrate into damaged tissue can remain functional long-term — replacing the role of the damaged cells they substitute for. This is what makes them a tissue-replacement therapy rather than a temporary signaling therapy.
MUSE cells were discovered in 2010 by Professor Mari Dezawa and her research team at Tohoku University Graduate School of Medicine in Sendai, Japan. The original paper was published in the Proceedings of the National Academy of Sciences (PNAS).
Yes. In regenerative medicine, combination protocols typically outperform single-agent therapy. MUSE cells are commonly combined with exosomes (which trigger gene expression and prepare tissue for repair), standard MSCs (for inflammation control), and supportive IV nutrition. The Stem Cell Club builds personalized protocols during your consultation.
The Stem Cell Club offers MUSE cell therapy across our growing network of U.S. clinics. Our flagship locations are in St. George, Utah (640 E. 700 S. Ste 304) and Las Vegas, Nevada (9830 W. Tropicana Ave Ste 165), and we also offer MUSE cell therapy through co-branded partner clinics in additional states. Every network clinic uses the same APEX™ MUSE Cell product, the same clinical protocols, and the same transparent pricing. Schedule a free consultation by calling (435) 281-2999 and we'll match you with the closest network location.
MUSE-cell-derived exosomes are small extracellular vesicles (typically 30–150 nm) released by MUSE cells, carrying proteins, lipids, and microRNAs. They mediate cell-to-cell communication and can trigger regenerative gene expression in recipient cells. Their effects can persist up to 21 days after administration, even though the exosomes themselves are cleared much faster. They are an active area of research, particularly for delivery to the brain via intranasal administration.
MUSE cell therapy remains investigational in the United States. It is not currently FDA-approved for any specific indication. The treatment is offered by licensed clinics under physician supervision, with patients receiving informed consent that explains the investigational nature of the protocol. The largest body of clinical research on MUSE cells has been conducted in Japan, which has the world's most advanced regulatory framework for regenerative medicine.
Tissue regeneration is a biological process — not a switch. Most patients begin to notice changes in the first 4–8 weeks, with continued improvement over 3–6 months as new tissue integrates and matures. Some patients report earlier improvement in inflammation-related symptoms (energy, joint stiffness, brain fog) within the first two weeks. Outcomes vary significantly by individual and by condition.
Key Published Studies
Foundational and clinically significant publications in MUSE cell research.
Schedule Your MUSE Cell Consultation
Speak with a licensed nurse practitioner about whether MUSE cells, premium MSC therapy, or a combination protocol fits your specific condition. Honest answers. Transparent pricing. No high-pressure sales.
Or call us directly at (435) 281-2999
Important Medical Disclaimer: The information on this page is for educational purposes only and is not intended as medical advice, diagnosis, or treatment. MUSE stem cell therapy is investigational and has not been evaluated or approved by the FDA for any specific indication. References to clinical research describe published, peer-reviewed studies and do not constitute a claim that MUSE cell therapy will achieve similar results in every patient. Individual results vary. The Stem Cell Club does not guarantee specific outcomes. All treatments are administered under the supervision of licensed medical providers. Please consult with a qualified healthcare professional before pursuing any regenerative therapy. Statements regarding regenerative medicine reflect emerging research and are not intended to diagnose, treat, cure, or prevent any disease.
© The Stem Cell Club | APEX™ MUSE Cells | (435) 281-2999